May 24 (Reuters) - Hungary's Gedeon Richter Plc GDRB.BU says in statement published on Budapest Stock Exchange web site:
* SIGNS LICENSE AGREEMENT TO COMMERCIALISE SCHIZOPHRENIA DRUG CARIPRAZINE IN AUSTRALIA AND NEW ZEALAND WITH CSL CSL.AX SUBSIDIARY SEQIRUS
* EXCLUSIVE AGREEMENT SAYS RICHTER RESPONSIBLE FOR PRODUCT SUPPLY, SEQIRUS FOR REGISTRATION AND COMMERCIALISATION IN AUSTRALIA, NEW ZEALAND
* RICHTER WILL RECEIVE UNSPECIFIED UPFRONT PAYMENT AND MILESTONE PAYMENTS FROM SEQIRUS Further company coverage: GDRB.BU CSL.AX